Ajooni Biotech Limited (AJOONI)
₹3.02 -1.31% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Ajooni Biotech's revenue was ₹63.5 Cr (+103.0% year on year, +4.7% on the previous quarter), and net profit ₹0.4 Cr (-44.6% year on year); the operating margin was 2.6%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹63.5 | +103.0% | +4.7% |
| Operating profit | ₹1.7 | +135.3% | +65.4% |
| Net profit | ₹0.4 | -44.6% | -54.5% |
| EPS (₹) | 0.01 | -80.0% | -83.3% |
| Operating margin | 2.6% | — | — |
AJOONI delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 79.95% of the AJOONI shares traded on NSE were taken to delivery, against the stock's own 20-session average of 74.67%. That is close to its usual level. Turnover was only ₹6 lakh, so a handful of trades can move this figure. Volume was 0.5 times its average, well below normal.
Delivery in the last 5 sessions: 71.1% · 75.0% · 84.0% · 52.7% · 80.0%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Ajooni Biotech Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. The certificate issued by Registrar and Share Transfer Agent (RTA) Cameo Corporate Services confirms that dematerialisation requests received during the quarter were duly processed and securities were listed. This is a periodic administrative filing with no impact on the company's financials (TTM revenue of Rs 215 Cr, market cap Rs 56 Cr).
- Compliance certificate issued under Regulation 74(5) for the quarter ended September 30, 2026
- Certificate issued by Registrar and Share Transfer Agent, Cameo Corporate Services Limited, dated October 6, 2026
- Confirmed that securities received for demat were verified, cancelled, and depositories updated within required timelines
- Filing pertains to ISIN INE820Y01021 under NSE symbol AJOONI
Ajooni Biotech reported standalone revenue from operations of Rs 63.49 Cr for the quarter ended June 30, 2026, representing a 103% YoY growth compared to Rs 31.27 Cr in Q1 FY26. However, net profit declined 44.7% YoY to Rs 0.43 Cr (vs Rs 0.78 Cr in Q1 FY26) due to raw material costs jumping to Rs 54.55 Cr and rising finance costs of Rs 0.48 Cr. Profit before tax contracted to Rs 0.65 Cr from Rs 1.03 Cr in the year-ago period. Current borrowings rose sharply to Rs 25.50 Cr as of June 30, 2026, up from Rs 16.22 Cr as of March 31, 2026.
- Revenue from operations rose 103.1% YoY to Rs 63.49 Cr (Rs 6,349.07 Lakhs) from Rs 31.27 Cr (Rs 3,126.77 Lakhs) in Q1 FY26
- Net profit fell 44.7% YoY to Rs 0.43 Cr (Rs 43.18 Lakhs) compared to Rs 0.78 Cr (Rs 78.14 Lakhs) in Q1 FY26
- Cost of materials consumed escalated to Rs 54.55 Cr (Rs 5,454.86 Lakhs) compared to Rs 25.64 Cr in Q1 FY26
- Current borrowings expanded by 57.2% to Rs 25.50 Cr (Rs 2,550.27 Lakhs) from Rs 16.22 Cr on March 31, 2026
Ajooni Biotech reported a significant 103% YoY revenue jump to Rs 63.49 Cr for the quarter ended June 30, 2026, compared to Rs 31.27 Cr in the previous year. However, Net Profit fell 45% YoY to Rs 0.43 Cr, down from Rs 0.78 Cr, primarily due to a sharp rise in finance costs and raw material expenses. The company's current borrowings increased by 57% during the quarter to Rs 25.50 Cr, while operating margins remain under pressure at approximately 1%.
- Revenue from operations increased 103% YoY to Rs 63.49 Cr from Rs 31.27 Cr.
- Net Profit declined 45% YoY to Rs 0.43 Cr from Rs 0.78 Cr in Q1 FY26.
- Finance costs surged 500% YoY to Rs 0.48 Cr from Rs 0.08 Cr.
- Current borrowings rose to Rs 25.50 Cr from Rs 16.22 Cr in March 2026.
- Property, Plant and Equipment increased by Rs 3.63 Cr to Rs 29.49 Cr, reflecting recent capex.
Ajooni Biotech has approved the allotment of 90,00,000 equity shares at a price of ₹4.30 per share, aggregating to ₹3.87 crore. The allotment was made via a preferential issue to a single entity, Healthy Biosciences Limited. The issue price of ₹4.30 is notably higher than the current market price of ₹3.80. This capital infusion represents approximately 6.1% of the company's current market capitalization of ₹63 crore.
- Allotment of 90,00,000 equity shares at an issue price of ₹4.30 per share
- Total fundraise amount aggregates to ₹3,87,00,000 (₹3.87 crore)
- Issue price includes a premium of ₹2.30 per share on a face value of ₹2
- Single allottee for the entire issue: Healthy Biosciences Limited
Ajooni Biotech has received shareholder approval to increase its Authorised Share Capital to ₹70 crore, divided into 35 crore equity shares of ₹2 each. This procedural step was approved at the 16th Annual General Meeting held on July 29, 2026. The increase provides the necessary headroom for the company's previously stated plan to raise ₹40 crore via a rights issue. This capital is intended to strengthen the company's net worth and fund a ₹16.5 crore capacity expansion for high-margin feed supplements.
- Authorised Share Capital increased to ₹70,00,00,000 (₹70 crore)
- Total number of equity shares increased to 35,00,00,000 with a face value of ₹2 each
- Approval obtained via special resolution at the 16th AGM on July 29, 2026
- Move supports the planned ₹40 crore rights issue to strengthen net worth to ₹84 crore
Shareholders of Ajooni Biotech approved the re-appointment of Mr. Gursimran Singh as a Director during the 16th Annual General Meeting held on July 29, 2026. Mr. Singh, who has served as the company's CEO for the past 8 years, was retiring by rotation and offered himself for re-appointment. The resolution was passed as an ordinary resolution, ensuring leadership continuity as the company pursues its 25-30% growth target. This administrative move maintains the current management structure during a period of planned capacity expansion.
- Re-appointment of Mr. Gursimran Singh approved at the 16th Annual General Meeting held on July 29, 2026
- Mr. Singh has served as the CEO of Ajooni Biotech for the past 8 years
- Director brings over 15 years of experience in Animal Husbandry and livestock supplements
- Voting results and scrutinizer report were officially declared on July 31, 2026
Ajooni Biotech has received shareholder approval at its 16th AGM to increase its Authorised Share Capital to Rs 70 crore. The amendment to the Memorandum of Association (MOA) increases the total authorized equity shares to 35 crore with a face value of Rs 2 each. This procedural step provides the necessary headroom for future equity issuance, aligning with the company's previously stated strategy to raise Rs 40 crore via a rights issue. The resolution was passed as a special resolution on July 29, 2026.
- Authorised Share Capital increased to Rs 70,00,00,000 (70 Cr)
- Total authorized equity shares set at 35,00,00,000 (35 Cr) units
- Face value of shares maintained at Rs 2 per share
- Special resolution passed during the 16th AGM held on July 29, 2026
- Voting results and scrutinizer report finalized on July 31, 2026
Ajooni Biotech's shareholders have approved the issuance of 90,00,000 equity shares on a preferential basis at the 16th Annual General Meeting. The issue price of Rs 4.30 per share represents a premium over the current market price of Rs 4.0. This fundraise will inject approximately Rs 3.87 crore into the company, representing about 5.9% of its current market capitalization. The capital is likely intended to support the company's ongoing expansion into high-margin animal feed supplements.
- Approval for issuance of 90,00,000 equity shares on a preferential basis
- Issue price fixed at Rs 4.30 per share, which is above the current market price of Rs 4.0
- Total fundraise magnitude estimated at Rs 3.87 crore
- Shareholder approval secured via special resolution at the AGM held on July 29, 2026
- Fundraise represents approximately 4.25% of the company's current net worth of Rs 91 crore
Ajooni Biotech Limited has submitted the voting results for its 16th Annual General Meeting (AGM) held on July 29, 2026. All 4 resolutions proposed to the shareholders were passed with the requisite majority. This is a standard procedural filing following the conclusion of the company's annual meeting. The company currently operates with a market capitalization of Rs 66 Cr and reported a TTM revenue of Rs 182 Cr.
- 16th Annual General Meeting successfully conducted on July 29, 2026
- Total of 4 resolutions were placed before and passed by the shareholders
- Voting results submitted in compliance with Regulation 44(3) of SEBI LODR
- Scrutinizer report issued by M/s. MR CHECHI and Associates confirmed the majority vote
Ajooni Biotech concluded its 16th AGM on July 29, 2026, where shareholders voted on four key resolutions including a preferential issue of equity shares. This capital raise follows a strong FY26 performance where revenue grew ~59% to Rs 182.38 Cr. The company is currently executing a strategic shift toward high-margin (9-10%) feed supplements supported by a new Rs 16.5 Cr factory. Investors should note that while the fundraise supports growth, it will lead to equity dilution in a company with a relatively low promoter holding of 26.9%.
- Shareholders approved a special resolution for the issuance of equity shares on a preferential basis
- Proposal to increase the authorized share capital was placed before the 60,449 shareholders of record
- FY26 revenue reached Rs 182.38 Cr, a significant jump from Rs 114.68 Cr in FY25
- The company is targeting a medium-term margin expansion to 4.5-6.0% through specialized supplements
- The AGM proceedings were conducted via video conferencing and concluded within 21 minutes
Ajooni Biotech has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document, issued by Registrar and Share Transfer Agent (RTA) Cameo Corporate Services Limited, confirms that physical share certificates received for dematerialization during the quarter ended June 30, 2026, were processed and cancelled. This is a standard administrative filing required for all listed entities to ensure the integrity of the share registry. It has no impact on the company's financial performance or operational outlook.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Confirmation that securities received for dematerialization were mutilated and cancelled
- Registrar and Share Transfer Agent (RTA) identified as Cameo Corporate Services Limited
- Verification that the name of depositories has been substituted in the register of members
Ajooni Biotech has scheduled its 16th Annual General Meeting for July 29, 2026, to seek approval for a preferential allotment of 90 lakh shares to its promoter, Healthy Biosciences Limited. The issue is priced at ₹4.30 per share, totaling ₹3.87 Cr, which represents approximately 2.1% of the company's TTM revenue. Additionally, the company proposes increasing its authorized share capital by ₹20 Cr to ₹70 Cr, providing headroom for future equity expansion. This move aligns with the company's stated strategy to strengthen its net worth and fund its shift toward high-margin feed supplements.
- Preferential allotment of 90,00,000 equity shares to promoter entity Healthy Biosciences Limited
- Issue price fixed at ₹4.30 per share, including a premium of ₹2.30 per share
- Total fundraise amount of ₹3.87 Cr from the promoter group
- Proposed increase in Authorized Share Capital from ₹50 Cr to ₹70 Cr
- Relevant date for determining the minimum issue price set as June 29, 2026
Ajooni Biotech has scheduled its 16th Annual General Meeting (AGM) for July 17, 2026. In accordance with SEBI regulations, the company will close its Register of Members and Share Transfer Books from July 23, 2026, to July 29, 2026. The cut-off date to determine eligibility for remote e-voting and polling at the AGM is set for July 17, 2026. This is a standard administrative procedure and does not reflect any change in the company's financial position or business operations.
- 16th Annual General Meeting (AGM) to be held on July 17, 2026
- Book closure period spans 7 days from July 23, 2026, to July 29, 2026
- Cut-off date for e-voting eligibility is July 17, 2026
- Filing made pursuant to Regulation 42 of SEBI (LODR) Regulations, 2018
Ajooni Biotech's Board has approved an increase in the company's Authorised Share Capital to Rs 70 crore, up from an undisclosed previous limit. This change involves creating a total of 35 crore equity shares with a face value of Rs 2 each. The proposal is subject to shareholder approval at the Annual General Meeting (AGM) scheduled for July 29, 2026. This administrative step is a prerequisite for the company's stated strategy to raise Rs 40 crore via a rights issue to fund its Rs 16.5 crore capacity expansion.
- Authorised Share Capital proposed to be increased to Rs 70,00,00,000 (Rs 70 Cr)
- Total equity shares to be increased to 35,00,00,000 shares at Rs 2 face value each
- Shareholder approval for the amendment to be sought at the AGM on July 29, 2026
- Supports the planned Rs 40 Cr rights issue intended to strengthen net worth to Rs 84 Cr
Ajooni Biotech's board has approved a preferential issue of 90 lakh equity shares to a promoter group entity, Healthy Biosciences Limited, at a price of ₹4.30 per share. This ₹3.87 crore infusion will increase the promoter holding from 26.89% to 30.53%, signaling increased promoter commitment. To facilitate this and future requirements, the company is also increasing its authorized share capital from ₹50 crore to ₹70 crore. The proposal is subject to shareholder approval at the upcoming AGM on July 29, 2026.
- Preferential allotment of 90,00,000 equity shares to promoter group entity Healthy Biosciences Limited
- Issue price fixed at ₹4.30 per share, representing a total fundraise of ₹3.87 crore
- Promoter shareholding to increase by 3.64 percentage points to 30.53% post-issue
- Authorized share capital increased by 40% from ₹50 crore to ₹70 crore
- Public shareholding will be diluted from 73.11% to 69.47% following the allotment
Financial Performance
Revenue Growth by Segment
Standalone revenue from operations for H1 FY26 (ended September 30, 2025) was INR 63.00 Cr, representing a 22.6% growth compared to INR 51.38 Cr in H1 FY25. The company operates in a single business segment (animal feed), making segment-wise growth identical to overall growth.
Geographic Revenue Split
Not explicitly disclosed in percentages, but operations and manufacturing facilities are concentrated in Punjab (Mohali and Khanna), serving the regional livestock market.
Profitability Margins
Profit Before Tax (PBT) for H1 FY26 was INR 2.26 Cr, a margin of 3.59%. Operating margins have historically been volatile between 3-4% due to raw material price fluctuations but are projected to improve to 4.5-6.0% over the medium term as high-margin products scale.
EBITDA Margin
Operating margin was reported at 1.06% for the first nine months of FY24, significantly impacted by an inventory loss of INR 1.9 Cr due to floods. Normalised margins are expected to recover to 3.5-4.0% for the full fiscal year.
Capital Expenditure
The company is executing a capital expenditure plan of INR 16.5 Cr for a new factory to enhance production capacity, which is expected to be operational by April 2025.
Credit Rating & Borrowing
CRISIL upgraded the company's rating to 'CRISIL BB+/Stable' from 'CRISIL BB/Stable'. The capital structure is supported by low gearing of 0.09x and an interest coverage ratio of approximately 7 times.
Operational Drivers
Raw Materials
Key raw materials include de-oiled rice bran, maize, bran, and mustard. Cost of materials consumed in H1 FY26 was INR 50.57 Cr, accounting for 80.3% of total revenue.
Import Sources
Raw materials are primarily sourced from domestic agricultural markets in Northern India, specifically Punjab and surrounding states.
Capacity Expansion
Current capacity is being expanded with a new factory (INR 16.5 Cr capex) slated for completion by April 2025 to meet growing demand for compound animal feed.
Raw Material Costs
Raw material costs grew 12.5% YoY in H1 FY26 to INR 50.57 Cr. Procurement strategies focus on cost efficiency methods to mitigate the impact of high fragmentation in the supplier market.
Manufacturing Efficiency
The company is focusing on incremental sales of feed supplements which provide higher margins of 9-10% compared to standard cattle feed.
Logistics & Distribution
Distribution is managed from the central works in Khanna, Punjab, primarily targeting the regional dairy and livestock industry.
Strategic Growth
Expected Growth Rate
25-30%
Growth Strategy
Growth will be driven by a rights share issue of INR 40 Cr in FY25 to strengthen net worth to INR 84 Cr, capacity enhancement via a new INR 16.5 Cr factory, and a strategic shift toward high-margin (9-10%) feed supplements.
Products & Services
Compound animal feed including cattle feed, cattle feed chips, camel feed, cotton oil cake, mustard oil cake, and specialized feed supplements.
Brand Portfolio
AJOONI
New Products/Services
Expansion into specialized feed supplements is expected to contribute significantly to the medium-term margin target of 4.5-6.0%.
Market Expansion
Targeting increased market share in the animal healthcare and nutrition space through the new production facility operational by Q1 FY26.
External Factors
Industry Trends
The industry is shifting toward compound feed and nutritional supplements to improve livestock yield. The company is positioning itself to capture this 9-10% margin segment.
Competitive Landscape
The market is highly fragmented with many small-scale unorganized players, leading to intense price competition.
Competitive Moat
The moat is built on the extensive experience of promoter Mr. Jasjot Singh and established customer relationships, supported by a very low-debt financial profile (0.09x gearing).
Macro Economic Sensitivity
Highly sensitive to agricultural commodity inflation and monsoon patterns affecting raw material availability and pricing.
Consumer Behavior
Increasing awareness among dairy farmers regarding the benefits of balanced nutrition for cattle is driving demand for compound feed over traditional fodder.
Geopolitical Risks
Low direct impact as operations are primarily domestic and focused on the regional agricultural economy.
Regulatory & Governance
Industry Regulations
Operations are governed by the Companies Act 2013 and agricultural manufacturing standards. The company maintains proper board processes and compliance mechanisms.
Environmental Compliance
The company maintains compliance with applicable statutory provisions; no specific ESG cost values were disclosed.
Taxation Policy Impact
Current tax liabilities were INR 0.32 Cr as of September 30, 2025.
Legal Contingencies
No major pending court cases or case values were disclosed. Minor procedural delays were noted in SEBI filings, such as a 48-hour delay in publishing Q1 FY25 results.
Risk Analysis
Key Uncertainties
Volatility in raw material prices (maize, mustard) and potential for environmental disruptions (floods) represent the primary business risks with a potential 2-3% impact on margins.
Geographic Concentration Risk
High concentration in Punjab, with 100% of manufacturing and the majority of revenue derived from the Northern Indian region.
Third Party Dependencies
Dependency on agricultural commodity suppliers; however, no single supplier dependency was highlighted as a critical risk.
Technology Obsolescence Risk
Low risk given the nature of the animal feed industry, though the company is adopting cost-efficiency technologies in its new factory.
Credit & Counterparty Risk
Receivables decreased by INR 0.40 Cr in H1 FY26, indicating stable collection cycles and healthy counterparty credit quality.
